Seattle-based Neoleukin Therapeutics is harnessing protein design technology to develop immunotherapies for cancer, inflammation, and autoimmunity disorders. At the forefront of the company's development is NL-201, a de novo protein designed to imitate the therapeutic activity of cytokines interleukin (IL)-2/IL-15 for treating renal cell carcinoma and melanoma. Formerly known as Aquinox Pharmaceuticals, the biopharmaceutical firm changed its name to Neoleukin Therapeutics in August last year. The company, founded in 2003, aims to carve out its niche in the immunotherapy space.